Gynesonics pulls in $43 mln

Redwood City, California-based Gynesonics, a women’s healthcare company focused on developing solutions for treating uterine fibroids, has secured $43 million in funding. Endeavour Vision and Abingworth led the round with participation from HealthCrest, InterWest Partners, Advanced Technology Ventures, HBM Partners, Correlation Ventures and Hercules Technology Growth Capital.


Chiasma snags $70 mln Series E

Chiasma Inc has received $70 million in Series E financing. The investors included Rock Springs Capital, Sofinnova Ventures, MPM Capital, F2 Capital, 7 Med Health Ventures, Abingworth and ARCH Venture Partners. Headquartered in Newton, Massachusetts and Jerusalem, Chiasma is a biopharmaceutical firm focused on treating acromegaly.


Lightspeed Venture leads $33 mln Series C funding in Personalis

Lightspeed Venture Partners has led a $33 million Series C funding round in Personalis, Inc., a genomics-based clinical diagnostic laboratory. All the Series A investors participated in the funding round, including Abingworth and Mohr Davidow Ventures. The funding brings Personalis’ total funding to $75 million.

Abingworth names von Emster a partner

Abingworth said Friday that Kurt von Emster was named a partner effective January 5th. He will be based in Menlo Park and will help source and manage deals in early-stage and late-stage venture capital, venture growth and public market investments including VIPEs. London-based Abingworth is an investment group that focuses on life sciences and healthcare.

Abingworth promotes Ken Haas and Vin Miles to partners

Abingworth has promoted Ken Haas and Vin Miles to partners. They are both based in the US where they source and manage deals including early stage and late stage venture capital, venture growth and public market investments as well as VIPEs (venture investments in public equities).


Pixium Vision launches IPO on Euronext Paris

Pixium Vision has launched its Initial Public Offering on Euronext’s regulated market in Paris. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Proteon Therapeutics grabs $45 mln Series D

Proteon Therapeutics said Friday that it has raised $45 million in Series D financing. Abingworth led the round with participation from Deerfield Management Company, Pharmstandard International S.A., TVM Capital, Prism VentureWorks, Skyline Ventures, Intersouth Partners, MPM Capital, Devon Park Bioventures, Bessemer Venture Partners and the Vectis Healthcare and Life Sciences Fund. In addition to the funding, Tim Haines, a partner at Abingworth, and Dmitry Kobyzev, an investment manager at Inbio Ventures, have been added to Proteon Therapeutics’ board of directors. Headquartered in Waltham, Mass., Proteon Therapeutics is a biopharmaceutical firm focused on treating kidney and vascular diseases.

Pixium hires new CEO and director

Pixium has appointed Khalid Ishaque as CEO and director. Previously, Ishaque worked at Boston Scientific where he most recently served as general manager of its neuromodulation international business. Based in Paris, Pixium is a maker of vision restoration systems for the blind. Its backers include Sofinnova Partners, Omnes Capital, Abingworth, Global Life Sciences Ventures, Bpifrance, Seventure and Polytechnos.

Pixium Vision raises funds led by Sofinnova

Pixium Vision, a developer of innovative retinal implant systems, has closed a Series A extension financing. This round was led by Sofinnova Partners, with support from Bpifrance, through the InnoBio fund, and existing series A investors Omnes Capital and Abingworth. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance have joined the Pixium board of directors.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Avedro Completes $43m Series D

Avedro has completed a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro’s other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures. As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the board of directors.

Labcyte Closes $5.3m Financing

Labcyte, a privately-held company advancing acoustic liquid handling, has closed a Series D financing led by the healthymagination fund, a part of GE Ventures. The $5.3 million round also included current Labcyte investors – Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors and H&Q Life Sciences Investors.

Celgene to Acquire Avila Therapeutics

Summit, New Jersey-headquartered Celgene Corporation is to acquire Avila Therapeutics, a privately held biotechnology company. Avila is backed by Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners. PRESS RELEASE Celgene Corporation (NASDAQ: CELG) and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through […]

Prosensa Raises Funding Round

Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases, has raised €23 million (US$29.8 million) in new equity financing. The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. PRESS RELEASE Prosensa, the Dutch biopharmaceutical […]

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget